Plasma Apheresis Machines

Global Plasma Apheresis Machines Market to Reach US$22.1 Billion by 2030

The global market for Plasma Apheresis Machines estimated at US$13.1 Billion in the year 2024, is expected to reach US$22.1 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Plasma Collection System, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$15.1 Billion by the end of the analysis period. Growth in the Multi-Component Collection System segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 14.4% CAGR

The Plasma Apheresis Machines market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.9 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Plasma Apheresis Machines Market - Key Trends & Drivers Summarized

Why Are Plasma Apheresis Machines Becoming Indispensable in Therapeutic and Donor Applications?

Plasma apheresis machines-critical devices that separate plasma from whole blood-are increasingly being deployed across donor centers, transfusion medicine, and clinical therapy settings. These machines enable both autologous plasma exchange and donor plasma collection, playing a vital role in managing autoimmune diseases, hematological disorders, and plasma protein therapies. As global demand for immunoglobulins, albumin, clotting factors, and convalescent plasma rises, plasma apheresis systems are becoming the cornerstone of the plasma-derived therapeutics value chain.

Therapeutically, plasma apheresis (or plasmapheresis) is used in the treatment of conditions such as myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barre syndrome, and lupus. It helps remove pathogenic autoantibodies, immune complexes, or excess proteins from circulation. In donor settings, these machines allow for the collection of high-purity plasma while returning other blood components-minimizing donor fatigue and enabling higher collection frequency. This operational efficiency is critical for biopharmaceutical manufacturers relying on plasma fractionation to produce life-saving biologics.

The COVID-19 pandemic also brought renewed attention to convalescent plasma therapy, temporarily driving up demand for plasma apheresis systems in hospitals and blood centers. Even as such therapies are phased out, the event underscored the strategic importance of scalable and efficient plasma collection infrastructure.

What Technological Advances Are Enhancing Efficacy and Patient Safety in Apheresis Procedures?

The design and performance of plasma apheresis machines have undergone substantial innovation over the past decade. Modern systems use automated centrifugal or membrane-based separation techniques governed by precise software-controlled flow rates, anticoagulant dosing, and real-time monitoring. Brands such as Terumo BCT (Trima Accel), Fresenius Kabi (Amicus), and Haemonetics have launched next-generation machines with enhanced throughput, user-friendly interfaces, and integrated safety alerts.

Membrane filtration-based devices, though less common than centrifugal models, are gaining interest for selective plasma removal (e.g., therapeutic plasma exchange without cellular loss). These machines are increasingly used in pediatric care, intensive care units, and niche hematology applications. Dual needle access, disposable kits with closed-loop tubing, and RFID-enabled component tracking are now standard features across leading models-ensuring infection control and patient traceability.

Software upgrades are also enabling remote diagnostics, data capture, and integration with hospital EMR systems. AI-based flow optimization, automated pressure balancing, and personalized treatment algorithms are being incorporated into clinical settings to reduce procedure times and improve patient comfort. These advances are not only improving clinical outcomes but also optimizing workflow in high-throughput donation centers.

Which Clinical Settings and Regional Markets Are Accelerating Equipment Deployment?

The plasma apheresis market is highly active in North America, Europe, and select Asian countries where both donation and therapeutic applications are well established. The U.S. is the single largest market, supported by a vast network of commercial plasma donation centers operated by companies like CSL Plasma, Grifols, and Octapharma. These centers require highly reliable apheresis machines capable of operating under high daily volumes with minimal maintenance downtime.

In Europe, Germany, Austria, and the UK lead clinical use, particularly in autoimmune and nephrology centers. In Asia-Pacific, Japan, South Korea, and China are seeing increasing equipment procurement, both for therapeutic applications and to support domestic plasma fractionation. India, while still emerging, has seen a surge in demand driven by rising autoimmune disease prevalence and expanded private hospital infrastructure.

Hospital settings dominate therapeutic apheresis deployment, while donor centers, mobile blood units, and standalone plasma banks represent the bulk of equipment demand for collection. The growing focus on personalized medicine, rising incidences of rare immunological disorders, and expansion of blood transfusion networks in emerging markets are contributing to broader system adoption across diverse healthcare environments.

What Is Driving Growth in the Global Plasma Apheresis Machines Market?

The growth in the global plasma apheresis machines market is driven by increasing demand for plasma-derived biologics, expansion of donor plasma collection infrastructure, and broader adoption of therapeutic apheresis in clinical protocols. As healthcare systems recognize the importance of plasma-based treatments in managing chronic and autoimmune conditions, the need for efficient and safe apheresis machines continues to grow.

Technological enhancements in separation efficiency, donor comfort, and infection control are making apheresis more accessible and scalable. Biopharma expansion into plasma-derived product manufacturing is prompting private investments into donor centers and blood collection modernization, particularly in the U.S., China, and Latin America. Furthermore, favorable reimbursement frameworks, rising prevalence of neurological and hematological disorders, and increased government focus on self-sufficiency in plasma supply are fueling procurement of advanced apheresis devices.

With the convergence of clinical demand, regulatory support, and industry innovation, plasma apheresis machines are no longer niche medical equipment-they are vital components in modern transfusion medicine and personalized therapy ecosystems. Their global relevance is set to rise as plasma therapeutics and autoimmune disease management gain further traction.

SCOPE OF STUDY:

The report analyzes the Plasma Apheresis Machines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Plasma Collection System, Multi-Component Collection System); Application (Extracorporeal Therapy Application, Plasma Donation Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Asahi Kasei Medical
• B. Braun Melsungen AG
• Baxter International
• Cerner Corporation
• Cerus Corporation
• Fresenius Kabi
• Haemonetics Corporation
• Haier Biomedical
• HemaCare (Charles River)
• Kaneka Corporation
• Kawasumi Laboratories
• MacoPharma
• Medica S.p.A.
• Miltenyi Biotec
• Nikkiso Co., Ltd.
• Nigale Corporation
• Scinomed
• Shanghai Dahua Medical
• Terumo BCT
• Thermo Fisher Scientific

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more